These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18003610)

  • 1. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist.
    Shibata H; Yoshioka Y; Ohkawa A; Minowa K; Mukai Y; Abe Y; Taniai M; Nomura T; Kayamuro H; Nabeshi H; Sugita T; Imai S; Nagano K; Yoshikawa T; Fujita T; Nakagawa S; Yamamoto A; Ohta T; Hayakawa T; Mayumi T; Vandenabeele P; Aggarwal BB; Nakamura T; Yamagata Y; Tsunoda S; Kamada H; Tsutsumi Y
    J Biol Chem; 2008 Jan; 283(2):998-1007. PubMed ID: 18003610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists.
    Mukai Y; Nakamura T; Yoshioka Y; Shibata H; Abe Y; Nomura T; Taniai M; Ohta T; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
    J Biochem; 2009 Aug; 146(2):167-72. PubMed ID: 19386778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
    Mukai Y; Shibata H; Nakamura T; Yoshioka Y; Abe Y; Nomura T; Taniai M; Ohta T; Ikemizu S; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
    J Mol Biol; 2009 Jan; 385(4):1221-9. PubMed ID: 19084540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics.
    Inoue M; Tsuji Y; Yoshimine C; Enomoto S; Morita Y; Osaki N; Kunishige M; Miki M; Amano S; Yamashita K; Kamada H; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2020 Jul; 295(28):9379-9391. PubMed ID: 32398258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification.
    Inoue M; Ando D; Kamada H; Taki S; Niiyama M; Mukai Y; Tadokoro T; Maenaka K; Nakayama T; Kado Y; Inoue T; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2017 Apr; 292(16):6438-6451. PubMed ID: 28235800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF.
    Shibata H; Yoshioka Y; Abe Y; Ohkawa A; Nomura T; Minowa K; Mukai Y; Nakagawa S; Taniai M; Ohta T; Kamada H; Tsunoda S; Tsutsumi Y
    Biomaterials; 2009 Dec; 30(34):6638-47. PubMed ID: 19765818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.
    Nomura T; Abe Y; Kamada H; Shibata H; Kayamuro H; Inoue M; Kawara T; Arita S; Furuya T; Yamashita T; Nagano K; Yoshikawa T; Yoshioka Y; Mukai Y; Nakagawa S; Taniai M; Ohta T; Serada S; Naka T; Tsunoda S; Tsutsumi Y
    J Control Release; 2011 Jan; 149(1):8-14. PubMed ID: 20036293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models.
    Shibata H; Yoshioka Y; Ohkawa A; Abe Y; Nomura T; Mukai Y; Nakagawa S; Taniai M; Ohta T; Mayumi T; Kamada H; Tsunoda S; Tsutsumi Y
    Cytokine; 2008 Nov; 44(2):229-33. PubMed ID: 18815054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.
    Nomura T; Abe Y; Kamada H; Inoue M; Kawara T; Arita S; Furuya T; Minowa K; Yoshioka Y; Shibata H; Kayamuro H; Yamashita T; Nagano K; Yoshikawa T; Mukai Y; Nakagawa S; Tsunoda S; Tsutsumi Y
    Pharmazie; 2010 Feb; 65(2):93-6. PubMed ID: 20225650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity.
    Richter F; Liebig T; Guenzi E; Herrmann A; Scheurich P; Pfizenmaier K; Kontermann RE
    PLoS One; 2013; 8(8):e72156. PubMed ID: 23977237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2.
    Shibata H; Abe Y; Yoshioka Y; Nomura T; Sato M; Kayamuro H; Kawara T; Arita S; Furuya T; Nagano K; Yoshikawa T; Kamada H; Tsunoda S; Tsutsumi Y
    Cytokine; 2010 Apr; 50(1):75-83. PubMed ID: 20045350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning.
    Abe Y; Yoshikawa T; Inoue M; Nomura T; Furuya T; Yamashita T; Nagano K; Nabeshi H; Yoshioka Y; Mukai Y; Nakagawa S; Kamada H; Tsutsumi Y; Tsunoda S
    Biomaterials; 2011 Aug; 32(23):5498-504. PubMed ID: 21546081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel TNF-α receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice.
    Kitagaki M; Isoda K; Kamada H; Kobayashi T; Tsunoda S; Tsutsumi Y; Niida T; Kujiraoka T; Ishigami N; Ishihara M; Matsubara O; Ohsuzu F; Kikuchi M
    J Atheroscler Thromb; 2012; 19(1):36-46. PubMed ID: 22146239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Creation of TNFR1-selective antagonist and its therapeutic effects].
    Nomura T; Abe Y; Yoshioka Y; Nakagawa S; Tsunoda S; Tsutsumi Y
    Yakugaku Zasshi; 2010 Jan; 130(1):63-8. PubMed ID: 20046067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutants of lymphotoxin-α with augmented cytotoxic activity via TNFR1 for use in cancer therapy.
    Morishige T; Yoshioka Y; Narimatsu S; Ikemizu S; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
    Cytokine; 2013 Feb; 61(2):578-84. PubMed ID: 23246116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.
    Kontermann RE; Münkel S; Neumeyer J; Müller D; Branschädel M; Scheurich P; Pfizenmaier K
    J Immunother; 2008 Apr; 31(3):225-34. PubMed ID: 18317365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Japonicone A antagonizes the activity of TNF-α by directly targeting this cytokine and selectively disrupting its interaction with TNF receptor-1.
    Hu Z; Qin J; Zhang H; Wang D; Hua Y; Ding J; Shan L; Jin H; Zhang J; Zhang W
    Biochem Pharmacol; 2012 Dec; 84(11):1482-91. PubMed ID: 22981364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
    Qin W; Feng J; Li Y; Lin Z; Shen B
    Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration.
    Dong Y; Fischer R; Naudé PJ; Maier O; Nyakas C; Duffey M; Van der Zee EA; Dekens D; Douwenga W; Herrmann A; Guenzi E; Kontermann RE; Pfizenmaier K; Eisel UL
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12304-12309. PubMed ID: 27791020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy.
    Fujisawa S; Konnai S; Okagawa T; Maekawa N; Tanaka A; Suzuki Y; Murata S; Ohashi K
    BMC Vet Res; 2019 Feb; 15(1):68. PubMed ID: 30819151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.